Oncotarget: Providing Information About Cancer

Cancer has claimed billions of life on earth. It is one of the deadliest diseases that mankind has faced since prehistory, and up until now, a cure is yet to be discovered. Scientists from all over the world are doing their best order to eradicate the disease, and they are publishing their works on different platforms, and one of it is Oncotarget. Oncotarget is a publication that is being released weekly, and scientists coming from the same field of oncology are the ones reviewing the articles that are being included in the journal. It tackles everything about oncology present status, the development on cure, and other information relating to cancer. The journal was first released in 2010, and it is published through Impact Journals. The journal’s editors in chief are both coming from the Roswell Park Cancer Institute – Andrei V. Gudkov, and Dr. Mikhail Blagosklonny.

2. Mikhail Blagosklonny is known for his quest to discover the key for immortality by researching about rapamycin. This research was first made known to the scientific world through Oncotarget, and its publication helped get the attention of his fellow scientists, shifting their attention to this ongoing study. Other oncologists are also posting their discoveries, researches and studies on the journal, and it is being updated regularly to reflect these new entries. One of the most recent entries being published in the journal is the research coming from the Norris Cotton Cancer Center in Dartmouth about a new strategy that would kill cancer cells while sparing the normal, healthy ones. According to their study, cells which could mutate into a tumor can be detected and be differentiated from a normal cell, and by identifying them, they can be selected and eradicated.

Reading the journal would give its readers high hopes about sacrifice and the dedication that the oncologists are pouring into their profession. Oncotarget has been a tool for scientists to openly share their knowledge with their peers, showing their progress in the battle against cancer. With publications like Oncotarget, these scientists could speed up the discovery of the cure for cancer.

To know more visit @: www.tandfonline.com/doi/pdf/10.4161/cbt.8.9.8899

How Oncotarget has vouched to help save lives.

Formed in 2010, Oncotarget is an open English journal that specializes in educating the general public on issues dealing with cancer. Through this journal, people get to know how to prevent, care and treat cancer to avoid death in the future. In the modern world, cancer has become one the leading causes of death thus lead to many physicians trying to figure out the cure or how to prevent this deadly disease. When it comes to educating a large mass of people, it needs to be written by individuals who are well learned of the topic on hand to ensure people don’t get misdirected about the issue. With this in mind, Mikhail Blagoskloony and Andrei V. Gudkov are the editor in chief of the journal as they have the required knowledge when it comes to oncology. Both of the two editors in chief are educationists and researchers who share what they know and find in their research. Blagosklonny is now the Oncology professor at Roswell Park Cancer Institute. Oncotarget is also available on Dove Press.

Majorly, Oncotarget is seen to highlights all the research underway that is related to cancer ailment. When it comes to writing the journal, they majorly rely on the reviews to help in improving the areas that need to be improved. Through this, they get to determine the insight on the age group visit the site after it has been posted on the website where everybody can access. Not many people are aware of how Oncotarget works to enable them access the information. It is easy to access the information as it works when an individual highlights the required steps after reviewing the manuscripts.

Through Oncotarget, people have gotten the opportunity of learning more on matters dealing with cancer. According to many people, prevention is better than cure, and this is why many people want to learn about ways to prevent one from acquiring such an ailment.

Follow Oncotarget journal on Twitter.